Weiss Multi-Strategy Advisers’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-53,000	Closed	-$270K	–	701
2019 Q4	$270K	Buy	53,000 +3,000	+6%	+$15.9K	﹤0.01%	565
2019 Q3	$253K	Hold	50,000	–	–	0.01%	530
2019 Q2	$309K	Buy	50,000 +10,000	+25%	+$48.2K	0.01%	450
2019 Q1	$186K	Buy	+40,000	New	+$181K	﹤0.01%	482
2015 Q4	–	Sell	-91,000	Closed	-$521K	–	479
2015 Q3	$521K	Buy	91,000 +1,000	+1%	+$7.67K	0.02%	317
2015 Q2	$671K	Buy	+90,000	New	+$545K	0.03%	351

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Weiss Multi-Strategy Advisers's PGNX Position: Q1 2020 in Review

Weiss Multi-Strategy Advisers sold out of Progenics Pharmaceuticals Inc (PGNX) in Q1 2020, closing a stake of 53,000 shares — an estimated $270K sold.

Weiss Multi-Strategy Advisers first reported a position in PGNX in Q2 2015 and held it in 6 quarters. The position peaked at $671K in Q2 2015. 129 funds tracked by Wall St. Rank hold PGNX as of Q1 2020.

Weiss Multi-Strategy Advisers reported no remaining Progenics Pharmaceuticals Inc position as of Q1 2020 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 53,000 Progenics Pharmaceuticals Inc shares in Q1 2020, an estimated $270K.
Weiss Multi-Strategy Advisers first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 6 quarters.
Weiss Multi-Strategy Advisers's Progenics Pharmaceuticals Inc position peaked at $671K in Q2 2015.
129 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q1 2020.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2020, filed 15 May 2020.